Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Cytokinetics Inc (NASDAQ: CYTK) closed at $55.88 in the last session, down -0.34% from day before closing price of $56.07. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 0.81 million shares were traded. CYTK stock price reached its highest trading level at $56.065 during the session, while it also had its lowest trading level at $54.87.
Ratios:
We take a closer look at CYTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 7.28 whereas as Long-Term Debt/Eq ratio is at 7.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 13, 2024, Downgraded its rating to Neutral and sets its target price to $60 from $85 previously.
On January 24, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $61 to $92.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 05, 2024, whereas the target price for the stock was revised from $60 to $90.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 12 ’24 when Blum Robert I sold 11,500 shares for $55.17 per share. The transaction valued at 634,455 led to the insider holds 399,412 shares of the business.
PARSHALL B LYNNE sold 5,000 shares of CYTK for $276,000 on Aug 12 ’24. The Director now owns 20,600 shares after completing the transaction at $55.20 per share. On Aug 12 ’24, another insider, B LYNNE PARSHALL, who serves as the Director of the company, bought 5,000 shares for $55.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6574840832 and an Enterprise Value of 6330573312. For the stock, the TTM Price-to-Sale (P/S) ratio is 2100.59 while its Price-to-Book (P/B) ratio in mrq is 60.50. Its current Enterprise Value per Revenue stands at 2019.966 whereas that against EBITDA is -12.837.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is 1.70%, while the 200-Day Moving Average is calculated to be -6.63%.
Shares Statistics:
According to the various share statistics, CYTK traded on average about 2.02M shares per day over the past 3-months and 1423670 shares per day over the past 10 days. A total of 117.66M shares are outstanding, with a floating share count of 113.88M. Insiders hold about 3.28% of the company’s shares, while institutions hold 103.17% stake in the company. Shares short for CYTK as of 1722384000 were 17832699 with a Short Ratio of 8.81, compared to 1719532800 on 17377857. Therefore, it implies a Short% of Shares Outstanding of 17832699 and a Short% of Float of 23.200001.
